During our KUC weekly meeting, we listen to an excellent lecture from Dr. M. Mustafa, discussing cystic kidney diseases. She went on from classification, simple cysts, complex cysts, cystic renal neoplasms, Medullary sponge kidney and ADTKD.

Then she discussed ADPKD with its classifications, pathophysiology, genetic background, diagnosis and imaging modalities, Mayo TKV classification.

Next, she went on discussing treatment options, starting with intense blood pressure control with the (HALT-PKD study), effect of hydration, salt restriction, phosphate restriction, the end of Lanreotide with the (DIPAK studies), Tolvaptan, despite not present in Egypt yet, with the TEMPO3:4 and TEMPO 4:4 and REPRISE trials in all stages of CKD and the potential benefits and harms of SGLT2i in ADPKD.

She then finished by discussing the future options to treat ADPKD with Ketogenic diet, metformin (TAME-PKD), Bardoxolone (TSUBAKI trial).

You can view the full lecture here:

Regards,
Mohamed Elrggal, MD

Published by Dr.Essam

I am Mohamed Essam Elrggal, a consultant nephrology from Alexandria, Egypt. You can find me on twitter @M_Elraggal. Working as a nephrologist since 2010 @KUC (kidney and urology center). Currently the head of Al-Qabbary nephrology department.